Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 176 EUR -0.23% Market Closed
Market Cap: 13.2B EUR
Have any thoughts about
Sartorius AG?
Write Note

Gross Margin
Sartorius AG

44%
Current
50%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
44%
=
Gross Profit
1.5B
/
Revenue
3.3B

Gross Margin Across Competitors

Country DE
Market Cap 12.1B EUR
Gross Margin
44%
Country US
Market Cap 200.4B USD
Gross Margin
56%
Country US
Market Cap 191.7B USD
Gross Margin
67%
Country US
Market Cap 141.1B USD
Gross Margin
64%
Country US
Market Cap 134.3B USD
Gross Margin
69%
Country IE
Market Cap 104.7B USD
Gross Margin
65%
Country US
Market Cap 66.2B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.4B USD
Gross Margin
79%
Country CN
Market Cap 308.3B CNY
Gross Margin
64%
Country US
Market Cap 36.5B USD
Gross Margin
41%
No Stocks Found

Sartorius AG
Glance View

Market Cap
12.1B EUR
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SRT Intrinsic Value
184.25 EUR
Undervaluation 4%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
44%
=
Gross Profit
1.5B
/
Revenue
3.3B
What is the Gross Margin of Sartorius AG?

Based on Sartorius AG's most recent financial statements, the company has Gross Margin of 44%.